Cook Medical has announced the commercial availability of its Zilver PTX drug-eluting peripheral stent in a 6 French diameter delivery system and stent lengths up to 120mm to treat patients with peripheral artery disease in the superficial femoral artery.
“The introduction of the narrower 6 Fr delivery system and longer 120mm length versions of the Zilver PTX drug-eluting stent system represents a landmark for the treatment of superficial femoral artery disease. These advances will allow an extended use of stent technology for endovascular treatment of peripheral artery disease,” said Thomas Zeller, Bad Kroizingen, Germany.
The Zilver PTX drug-eluting stent is a combination therapy device for peripheral artery disease that first expands and holds open the artery to restore patency and then delivers the drug paclitaxel to limit cell reproduction without using a polymer to adhere the drug to the stent.
Randomised, prospective clinical data, presented at LINC 2011, have demonstrated that, over a 24-month period, this unique drug-device combination achieved a 50% reduction in restenosis compared with bare-metal stenting and continues to show effectiveness at 24 months with 74.8% primary patency.
Andy Förster, EMEA manager for Cook Medical’s Peripheral Intervention business unit, said, “Since the announcement of this data, adoption of the Zilver PTX has greatly increased. The longer lengths of Zilver PTX will further expand the options physicians have to treat patients.”
The CE marked Zilver PTX drug-eluting stent is under revision by the FDA for sale in the United States.